

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis

Diana Buitrago-Garcia^{*1, 2}

Aziz Mert Ipekci^{*1}

Leonie Heron^{*1}

Hira Imeri¹

Lucia Araujo-Chaveron^{3,4}

Ingrid Arevalo-Rodriguez⁵

Agustín Ciapponi⁶

Muge Cevik⁷

Anthony Hauser¹

Muhammad Irfanul Alam⁸

Kaspar Meili⁹

Eric A. Meyerowitz¹⁰

Nirmala Prajapati¹¹

Xueting Qiu¹²

Aaron Richterman¹³

William Gildardo Robles-Rodríguez¹⁴

Shabnam Thapa¹⁵

Ivan Zhelyazkov¹⁶

Georgia Salanti¹

Nicola Low¹

* These authors contributed equally to this work

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 31 1. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 32 2. Graduate School of Health Sciences, University of Bern, Bern, Switzerland
- 33 3. EHESP French School of Public Health La Plaine St Denis, Rennes, France
- 34 4. Institut Pasteur, Paris, France
- 35 5. Clinical Biostatistics Unit, Hospital Universitario Ramon y Cajal, IRYCIS, CIBER of Epidemiology
- 36 and Public Health, Madrid, Spain
- 37 6. Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina
- 38 7. Division of Infection and Global Health Research, School of Medicine, University of St. Andrews,
- 39 Fife, Scotland, United Kingdom
- 40 8. House 1066, 08 Lovelane, Chittagong 4000, Bangladesh
- 41 9. Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden
- 42 10. Division of Infectious Diseases, Montefiore Medical Center, Bronx, New York, United States of
- 43 America
- 44 11. Université Paris-Saclay, Paris, France
- 45 12. Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan
- 46 School of Public Health, Boston, United States of America
- 47 13. Division of Infectious Diseases, University of Pennsylvania, Philadelphia, United States of
- 48 America
- 49 14. Fundación Universitaria de Ciencias de la Salud. Bogotá, Colombia.
- 50 15. Manchester Centre for Health Economics, University of Manchester, Manchester, United
- 51 Kingdom
- 52 16. University of Sheffield, Sheffield, United Kingdom
- 53
- 54 Word counts: Abstract, 498; main text 5110; 2 tables; 3 figures; 155 references
- 55 Supplementary material: 2 text files; 5 tables; 18 figures; 1 checklist; 1 form
- 56 Corresponding author: nicola.low@ispm.unibe.ch

ABSTRACT

BACKGROUND

Debate about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We conducted a living systematic review to address three questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic?

METHODS AND FINDINGS

The protocol was first published on 1 April 2020 and last updated on 18 June 2020. We searched PubMed, Embase, bioRxiv and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 2 February 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 94 studies. Heterogeneity was high and we could not reliably estimate values for the proportion of asymptomatic infections overall (interquartile range 13-45%, prediction interval 2-89%), or in studies based on screening of defined populations (interquartile range 18-59%, prediction interval 3-95%). In screening studies at low risk of information bias, the prediction interval was 4-69% (summary proportion 23%, 95% CI 14-35%). In 40 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 18% (95% CI 14-24%, prediction interval 3-64%) and, in studies at low risk of selection bias, 25% (95% CI 18-33%, prediction interval 5-66%). (2) The

secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.43 (95% CI 0.05-3.44, 5 studies). (3) In 11 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity in studies that were not designed to measure persistently asymptomatic infection, high risks of selection and information bias, and the absence of studies about variants of concern or in people who have been vaccinated.

CONCLUSIONS

This review does not provide a summary estimate of the proportion of asymptomatic SARS-CoV-2 across all study designs. In studies based on contact and outbreak investigation, most SARS-CoV-2 infections were not persistently asymptomatic. Summary estimates from meta-analysis may be misleading when variability between studies is extreme. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by wild-type SARS-CoV-2.

REVIEW PROTOCOL: Open Science Framework (<https://osf.io/9ewys/>)

Introduction

There is ongoing debate about the true proportion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that remains asymptomatic [1]. A well-recognised source of overestimation arises when people without symptoms at the time of testing are reported as having asymptomatic infection, with such cross-sectional studies often reporting percentages of 80% or more [2, 3]. These studies overestimate the proportion of persistently asymptomatic infection because they misclassify people with so-called presymptomatic infection, who will develop symptoms of coronavirus disease 2019 (COVID-19) if reassessed after an adequate follow-up period [1]. Other sources of bias can result in over- or underestimation of the proportion with persistent asymptomatic infections, even when participants are adequately followed up [1]. For example, studies that assess a limited range of symptoms could overestimate the proportion asymptomatic through misclassification if they do not ask participants about all possible symptoms. Since COVID-19 was first identified as a viral pneumonia, the spectrum of symptoms has grown to include gastrointestinal symptoms and disturbances of smell and taste [1]. On the other hand, selection bias would be expected to underestimate the proportion with asymptomatic SARS-CoV-2 if people with symptoms are more likely to be tested for SARS-CoV-2 infection than those without symptoms [4].

Accurate estimates of the proportions of true asymptomatic and presymptomatic infections are needed to determine the balance and range of control measures [5]. Recognition of asymptomatic and presymptomatic infections has shown the importance of control measures such as physical distancing, active case-finding through testing of asymptomatic people [6] and the need for rapid quarantine [7]. The number of published studies about SARS-CoV-2 is increasing continuously and the types of published studies are also changing [8], including the designs of studies that report on the proportion of people with asymptomatic infection. In systematic reviews, reported estimates from random effects meta-analysis models range from 17 to 41% [9-14]. Authors of these reviews acknowledge high heterogeneity, typically reporting values of the I^2 statistic >90%, which is the

proportion of the variability between estimates due to study differences other than chance [15]. Sources of heterogeneity are often not explored in detail, however, with infrequent reporting of prediction intervals [9, 10], even though they give information about all between-study variability and show the range of estimates that would be expected in future studies [15]. In this fourth update of our living systematic review [10] we aimed to improve and understand the changing evidence over time for three review questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of people with asymptomatic and presymptomatic, compared with symptomatic SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection, or presymptomatic?

Methods

We conducted a living systematic review, a systematic review that provides an online summary of findings and is updated when relevant new evidence becomes available [16]. The protocol, which describes modifications for each update, was first published on 1 April 2020 and amended for this version on 18 June 2020, (<https://osf.io/9ewys/>). Previous versions of the review have been posted as preprints [17] and published as a peer-reviewed article [10]. We report our findings according to statements on preferred reporting items for systematic reviews and meta-analyses 2020 (S1 PRISMA 2020 Checklist) [18] and on synthesis without meta-analysis in systematic reviews (SWiM) [19]. Ethics committee review was not required for this review. Box 1 shows our definitions of symptoms, asymptomatic infection and presymptomatic status.

Box 1. Definitions of symptoms and symptom status in a person with SARS-CoV-2 infections

Symptoms: symptoms that a person experiences and reports. We used the authors' definitions. We searched included manuscripts for an explicit statement that the study participant did not report symptoms that they experienced. Some authors defined 'asymptomatic' as an absence of self-reported symptoms. We did not include clinical signs observed or elicited on examination.

Asymptomatic infection: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment and had no symptoms at the end of follow-up. The end of follow-up was defined as any of the following:

virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

Presymptomatic: a person with laboratory-confirmed SARS-CoV-2 infection, who has no symptoms, according to the authors' report, at the time of first clinical assessment, but who developed symptoms by the end of follow-up. The end of follow-up was defined as any of the following: virological cure, with one or more negative RT-PCR test results; follow-up for 14 days or more after the last possible exposure to an index case; follow-up for seven days or more after the first RT-PCR positive result.

Information sources and search

We conducted the first search on 25 March 2020 and updated it on 20 April 2020, 10 June 2020 and 2 February 2021. We searched the COVID-19 living evidence database [20], which uses automated workflow processes to: (1) provide daily updates of searches of four electronic databases (Medline, PubMed, Ovid Embase, bioRxiv and medRxiv), using medical subject headings and free-text keywords for SARS-CoV-2 infection and COVID-19; (2) de-duplicate the records; (3) tag records that are preprints; and (4) allow searches of titles and abstracts using Boolean operators. We used the search function to identify studies of asymptomatic or presymptomatic SARS-CoV-2 infection using a search string of medical subject headings and free text keywords (S1 Text). We also examined articles suggested by experts and the reference lists of retrieved studies. Reports were planned to be updated at 3-monthly intervals, with continuously updated searches.

Eligibility criteria

We included studies, in any language, of people with SARS-CoV-2 diagnosed by RT-PCR that documented follow-up and symptom status at the beginning and end of follow-up or investigated the contribution to SARS-CoV-2 transmission of asymptomatic or presymptomatic infection. We included contact tracing and outbreak investigations, cohort studies, case-control studies, and mathematical modelling studies. We amended eligibility criteria in the protocol for this update in two ways. First, we excluded studies that only reported the proportion of presymptomatic SARS-CoV-2 because the settings and methods of these studies were very different and their results were too heterogeneous to summarise [10]. Second, we aimed to reduce the risk of bias from studies with inclusion criteria based mainly on people with symptoms, which would systematically underestimate

the proportion of people with asymptomatic infection. We therefore excluded the following study types: case series restricted to people already diagnosed and studies that did not report the number of people tested for SARS-CoV-2, from whom the study population was derived. We also excluded case reports and contact investigations of single individuals or families, and any study without sufficient follow-up (Box 1). Where data from the same study population were reported in multiple records, we extracted data from the most comprehensive report.

Study selection and data extraction

Reviewers worked in pairs to screen records using an application programming interface in the electronic data capture system (REDCap, Vanderbilt University, Nashville, TN, USA). One reviewer applied eligibility criteria to select studies and a second reviewer verified all included and excluded studies. We reported the process in a flow diagram, adapted for living systematic reviews [21] (S1 Fig). The reviewers determined which of the three review questions each study addressed. One reviewer extracted data using a pre-piloted extraction form in REDCap and a second reviewer verified the extracted data. For both study selection and data extraction, a third reviewer adjudicated on disagreements that could not be resolved by discussion. We contacted study authors for clarification where the study description was insufficient to determine eligibility or if reported data in the manuscript were internally inconsistent. The extracted variables included, study design, country and/or region, study setting, population, age, sex, primary outcomes and length of follow-up (full list of variables in S1 Form). We extracted raw numbers of individuals with an outcome of interest and relevant denominators from empirical studies. From statistical and mathematical modelling studies we extracted proportions and 95% credibility intervals.

The primary outcomes for each review question were (1) the proportion of people with asymptomatic SARS-CoV-2 infection who did not experience symptoms at all during follow-up; (2) secondary attack rate from asymptomatic or presymptomatic index cases, compared with

symptomatic cases; (3) model-estimated proportion of SARS-CoV-2 transmission accounted for by people who are asymptomatic or presymptomatic.

Risk of bias in included studies

For this update, we developed a new tool to assess the risk of bias in studies estimating the proportion of asymptomatic infections because the study designs of included studies have changed over the course of the review. In previous versions, we used items from a tool to assess case series, which had dominated the literature early on [22] and from a tool assessing the prevalence of mental health disorders [23]. The new tool was based on possible biases in observational studies of prevalence in general and in COVID-19 in particular [4, 24]. We developed signalling questions in the domains of selection (two items), information (three items) and selective reporting (one item) biases (S2 Text). For mathematical modelling studies, we used a checklist for assessing relevance and credibility [25]. Two authors independently assessed the risk of bias, using a customised online tool, which saved responses into the REDCap database. A third reviewer resolved disagreements.

Synthesis of the evidence

The data extracted from the included studies and the code used to display and synthesise the results are publicly available: https://github.com/leonieheron/LSR_Asymp_v4. We used the *metaprop* and *metabin* functions from the *meta* package (version 4.11-0) [26] and the *ggplot2* package (version 3.3.5) in R (version 3.5.1) to display the study findings in forest plots and synthesise their results, where appropriate. The 95% confidence intervals (CI) for each study were estimated using the Clopper-Pearson method [27]. For review question 1, in studies that identified participants through investigation of contacts or in outbreak investigations, we subtracted the index cases from the total number of people with SARS-CoV-2 infection, because these people were likely to have been identified because of their symptoms and their inclusion might lead to underestimation of the asymptomatic proportion [14]. For all meta-analyses, we used stratified random effects models. Where a meta-analysis was not done, we present the interquartile range (IQR) and describe heterogeneity visually in forest plots, ordered by study sample size [19]. For statistical examination

of heterogeneity, we calculated the I^2 statistic, which is the approximate proportion of between-study variability that is due to heterogeneity other than chance and τ^2 , the between-study variance, which is used to generate the 95% prediction interval for the likely range of proportions that would be obtained in subsequent studies conducted in similar settings [15]. The protocol pre-specified subgroup analyses according to study design, setting and risk of bias. We did a χ^2 test to compare subgroups of studies assessed as being at low risk of bias in each domain versus those of unclear or high risk of bias of bias and between studies assessed as being at low risk of bias in all domains with those at unclear or high risk of bias in any domain. In additional analyses, we examined studies with at least ten cases of SARS-CoV-2 infection and according to publication date. To compare our findings with other studies, we extracted the raw data from three large systematic reviews [12-14] and calculated prediction intervals. For review question 2, as a measure of infectiousness, we calculated the secondary attack rate as the number of SARS-CoV-2-infected contacts as a proportion of all close contacts ascertained. For each included study, we compared the secondary attack rate from asymptomatic or presymptomatic index cases with that from symptomatic cases in the same study. If there were no events in a group, we added 0.5 to each cell in the 2x2 table. We did not account for potential clustering of contacts because the included studies did not report the number and size of infection clusters consistently. We used the Hartung-Knapp method for random effects meta-analysis to estimate a summary risk ratio (with 95% CI) [28]. For review question 3, we reported the findings descriptively because of large differences between study settings, methods and results. We did not construct funnel plots to examine bias across studies because their utility in studies reporting on proportions is not clear.

Results

The searches for studies about asymptomatic or presymptomatic SARS-CoV-2, on 25 March, 20 April and 10 June 2020 and 2 February 2021 resulted in 89, 230, 688 and 4,293 records for screening, respectively (S1 Fig). In the first version of the review [17], 11 articles were eligible for inclusion [7, 29-38], version 2 identified another 26 eligible records, version 3 [10] identified another 61 eligible

records and this update, version 4, identified another 74 articles [39-112]. Owing to the change in eligible study designs, this update excludes 66 articles from earlier versions, comprising 23 contact tracing studies or outbreak investigations, 39 screening studies, and four mathematical models (S1 Table). This review version included a total of 107 studies addressing one or more objectives; 94 empirical studies that estimate the proportion of people with asymptomatic SARS-CoV-2 (summarised in Table 1 and S2 Table) [39-48, 50-54, 56-80, 82-90, 92-97, 99-102, 104-138], five studies reporting on secondary attack rates [119, 129, 138-140], and 11 mathematical modelling studies reporting on the contribution of asymptomatic or presymptomatic infection to all SARS-CoV-2 transmission [7, 49, 55, 81, 91, 98, 103, 141-144].

Proportion of people with asymptomatic SARS-CoV-2 infection

The 94 studies reported on 16,193 people with SARS-CoV-2 infection (5,905 defined as having asymptomatic infection) in 31 countries [39-48, 50-54, 56-80, 82-90, 92-97, 99-102, 104-138] (Table 1). Thirty-two studies, including 9,121 infected people, were done in the United States (S3 Table). At time of the latest search date, 17 records were preprints, 14 of which had been published in peer-reviewed journals by 23 November 2021 [7, 49, 55, 89, 92, 98, 102, 105, 125, 126, 128, 133, 141, 145] and 3 were still preprints [95, 96, 144]. In all included studies, 86 followed participants for seven days or more, 19 followed participants for at least 14 days after a known exposure, 27 followed participants until they had at least one negative RT-PCR test and 29 studies used more than one method of follow-up (Table 1, S2 Table). Most studies included adults (39 studies) or people of all ages (35 studies); only three studies included children only [65, 69, 132] and seven included older adults [48, 71, 84, 94, 114, 121, 122]. Ten studies did not report the age of the participants. Only 15 studies reported the median age [39, 47, 57, 59, 61, 64, 86, 107, 118, 121, 123, 124, 127, 137, 145] and only 21 studies reported the sex distribution of people with asymptomatic SARS-CoV-2 [39, 40, 46, 48, 50, 57, 59, 61, 63, 64, 72, 86, 87, 107, 113, 118, 121, 123, 124, 127, 137] (Table 1, S2 Table). The types of included studies changed across the four versions of the review. In the first version [17], six of nine studies were contact tracing investigations of single-family clusters. In this version, two

270 main types of study design generated the study populations of people with SARS-CoV-2: contact
 271 tracing or outbreak investigation methods were used to identify and test potentially infected
 272 contacts (40 studies, referred to as contact and outbreak investigations); and studies that involved
 273 screening of a defined group of people in settings in the community, institutions, such as long-term
 274 care facilities, or occupational groups (54 studies, referred to as screening studies).

275 Table 1. Summary of characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections (review question 1)

		Study designs and settings					All studies
		Contact investigation	Outbreak investigation	Screening of defined study population			
				Community	Institutional	Occupational	
Total studies, n		12	28	17	24	13	94
Study characteristics ^a							
Publication date, n studies	January 2020 – June 2020	6	9	3	3	4	25
	July 2020 – December 2020	5	17	11	17	6	56
	January 2021 – June 2021	1	2	3	4	3	13
Region ^b , n studies	Africa	0	0	1	0	0	1
	Americas	4	9	3	12	5	33
	South-East Asia	0	3	1	1	1	6
	Europe	2	11	5	11	4	33
	Eastern Mediterranean	0	0	3	0	1	4
	Western Pacific	6	5	4	0	2	17
Follow-up method, n studies	14 days after last possible exposure	1	1	0	0	0	2
	≥7 days after diagnosis	4	16	8	18	6	52
	Until negative RT-PCR result	1	2	2	4	2	11
	Two or more follow-up methods	6	9	7	2	5	29
Age range of study participants	Children (<18 years), n studies	1	1	0	1	0	3
	Adults (18 – 65 years), n studies	2	9	7	10	11	39
	Older adults (>65 years), n studies	0	5	0	2	0	7
	All ages, n studies	7	12	7	8	1	35
	Not reported, n studies	2	1	3	3	1	10
Participant characteristics							
Total SARS-CoV-2 infections, n individuals		1055	4620	2378	7045	1095	16193
Total asymptomatic SARS-CoV-2 total, n individuals		246	1316	1093	3003	247	5905
Gender of asymptomatic cases (if available ^c)	Male, n	1	11	140	10	16	178
	Female, n	0	1	169	294	26	490

SARS-CoV-2, severe acute respiratory syndrome coronavirus.

^a S1 Table reports the characteristics of each study included for review question 1; ^b World Health Organization regions; ^c 80 studies did not report the gender of asymptomatic cases.

Between-study heterogeneity was considerable and we could not reliably estimate a range of plausible values for the proportion of asymptomatic infections for all included studies, or for screening studies (Fig 1). The IQR of estimates for all 94 included studies was 13-45% and the prediction interval from random-effects meta-analysis was 2-89% (S2 Fig). In studies enrolling people found through contact or outbreak investigations, for example in long-term care facilities, in aeroplanes, or on cruise ships, we estimated a summary estimate for the proportion asymptomatic (18%, 95% CI 14-24%, prediction interval 3-64%, IQR 8-35%, 40 studies [53, 60, 62, 65-68, 71, 73, 74, 82-86, 88, 90, 92, 93, 101, 105, 111, 112, 114-117, 119-123, 128-130, 132, 133, 136-138]. The estimated proportions of asymptomatic SARS-CoV-2 infections were similar in studies of contact investigations (16%, 95% CI 10-25%) and outbreak investigations (19%, 95% CI 14-26%) (S3 Fig).

[Fig 1]

In 54 screening studies, the IQR for estimates from individual studies was 18-59% and the prediction interval from random-effects meta-analysis was 3-95% [39-48, 50-52, 54, 56-59, 61, 63, 64, 69, 70, 72, 75-80, 88, 89, 94-97, 99, 100, 102, 104, 106-110, 113, 118, 124-127, 131, 134, 135]. We distinguished three settings in which screening studies were conducted; people in a community setting (17 studies, prediction interval 1-97%), institutional settings such as nursing homes (23 studies, prediction interval 5-95%), and occupational settings such as amongst groups of healthcare workers (13 studies, prediction interval 2-95%) (S3 Fig).

Risk of bias in individual studies

There were risks of bias in all types of empirical studies (S4 Fig). In pre-specified subgroup analyses according to risk of bias domains (Table 2), statistical heterogeneity remained very high ($I^2 \geq 84\%$) and the prediction intervals remained wide. In contact and outbreak investigations, the estimated proportion of asymptomatic individuals was associated with the risk of selection bias. In studies judged to be at low risk, 25% (95% CI 18-33%, prediction interval 5-66%) and 13% (95% CI 8-20%,

prediction interval 1-61%) in studies at unclear or high risk of bias ($p=0.02$ from χ^2 test for subgroup differences). In screening studies, heterogeneity was lower in studies judged to be at low risk of information bias in the assessment of symptoms ($p>0.01$, test for subgroup differences), with a summary estimate of the proportion asymptomatic of 23% (95% CI 14-35%, prediction interval 4-69%). Only nine studies were judged to be at low risk of bias in all domains, with some evidence of reduced heterogeneity ($p=0.05$, test for subgroup differences). For all other domains, estimates of heterogeneity were not associated with the assessment of the risk of bias.

Additional analyses

When restricted to studies with more than ten people with SARS-CoV-2 infection (S5 Fig), the estimated proportions with asymptomatic infection were very similar to the overall estimates (Fig 1, Table 2). The estimates of the proportion asymptomatic in the three periods of publication date were similar (S6 Fig, S7 Fig). In the three systematic reviews that we re-analysed, prediction intervals were: 1-83% (241 studies [12]); 4-97% (95 studies [13]); and 3-89% (170 studies [14]). I^2 values were between 94% and 99% (S4 Table).

Table 2. Summary of findings from subgroup analyses according to risk of bias in studies estimating the proportion of asymptomatic SARS-CoV-2 infections

Included studies		Contact and outbreak investigations					Subgroup diff, p value	Included studies	Screening of defined study population					Subgroup diff, p value
		n ^b	Summary estimate (95% CI)	Prediction interval	I ²	τ ²			n ^b	Summary estimate (95% CI)	Prediction interval	I ²	τ ²	
Risk of selection bias ^a	Low (S8 Fig)	22	0.25 (0.18-0.33)	0.05-0.66	84%	0.699	0.02	Low (S9 Fig)	16	0.40 (0.27-0.56)	0.05-0.90	93%	1.334	0.86
	Unclear/high (S8 Fig)	23	0.13 (0.08-0.20)	0.01-0.61	87%	1.214		Unclear/high (S9 Fig)	40	0.42 (0.29;0.57)	0.02-0.97	93%	3.271	
Risk of information bias ^a	Low (S10 Fig)	12	0.16 (0.08-0.30)	0.01-0.80	87%	1.664	0.68	Low (S11 Fig)	9	0.23 (0.14-0.35)	0.04-0.69	92%	0.612	<0.01
	Unclear/high (S10 Fig)	33	0.19 (0.14;0.25)	0.03-0.61	88%	0.865		Unclear/high (S11 Fig)	47	0.49 (0.33;0.59)	0.03-0.97	93%	2.935	
Risk of misclassification bias ^a	Low (S12 Fig)	35	0.17 (0.11-0.23)	0.02-0.69	88%	1.366	0.14	Low (S13 Fig)	41	0.41 (0.29-0.54)	0.03-0.95	94%	2.564	0.87
	Unclear/high (S12 Fig)	10	0.23 (0.18-0.29)	0.09-0.47	89%	0.194		Unclear/high (S13 Fig)	15	0.43 (0.23-0.66)	0.02-0.97	77%	2.849	
Risk of selective reporting bias ^a	Low (S14 Fig)	40	0.19 (0.14-0.25)	0.03-0.65	91%	0.992	0.18	Low (S15 Fig)	50	0.44 (0.32-0.56)	0.03-0.96	89%	2.807	0.18
	Unclear/high (S14 Fig)	5	0.11 (0.05-0.23)	0.00-0.76	88%	0.820		Unclear/high (S15 Fig)	6	0.27 (0.13-0.49)	0.01-0.91	98%	1.212	
All domains ^a	Low (S16 Fig)	6	0.20 (0.09-0.39)	0.01-0.85	92%	1.011	0.73	Low (S17 Fig)	3	0.17 (0.06-0.42)	0.00-1.00	89%	0.769	0.05
	Unclear/high (S16 Fig)	39	0.18 (0.09-0.39)	0.03-0.64	86%	1.032		Unclear/high (S17 Fig)	53	0.43 (0.32-0.55)	0.03-0.95	93%	2.641	

^a Assessed in the risk of bias tool (S2 Text), with full assessments in S4 Fig;^b n = number of clusters analysed, which exceeds the total number of studies.

Infectiousness of people with asymptomatic or presymptomatic SARS-CoV-2

Five of the studies that conducted detailed contact investigations provided enough data to calculate a secondary attack rate according to the symptom status of the index cases and to compare the secondary attack rates by symptom status (Fig 2) [119, 129, 138-140]. The updated search did not identify any new studies. Four studies compared the secondary attack rate from asymptomatic with symptomatic index cases (summary risk ratio 0.43 (95% CI 0.05-3.44, prediction interval 0-67%) [119, 129, 139, 140]. One study compared asymptomatic with presymptomatic index cases (summary risk ratio 0.19, 95% CI 0.02-1.46) [138] and three studies compared presymptomatic with symptomatic index cases (summary risk ratio 0.71 (95% CI 0.36-1.41, prediction interval 0.10-5.28) [119, 129, 139]. The risk of information bias, specifically in symptom assessment, was judged to be high or unclear in all five studies included (S4 Fig).

[Fig 2.]

Contribution of asymptomatic and presymptomatic infection to SARS-CoV-2 to transmission

We included 11 mathematical modelling studies (Fig 4) [7, 49, 55, 81, 91, 98, 103, 141-144]. Four studies were new [49, 81, 91, 98] and one study from the previous version [31] was replaced by a more recent analysis based on the same data [103]. The models in eight studies were informed by analyses of data from contact investigations in China, South Korea, Singapore, and from an outbreak on the *Diamond Princess* cruise ship, using data to estimate the serial interval or generation time [7, 49, 55, 91, 98, 103, 141, 142]. In the other three studies the authors did not analyse any original data sources [81, 143, 144].

Estimates of the contributions of both asymptomatic and presymptomatic infections SARS-CoV-2 transmission were very heterogeneous. For asymptomatic SARS-CoV-2 infection, three studies contributed four estimates [7, 55, 81]. Three estimates suggested a contribution to SARS-CoV-2 transmission of asymptomatic infection of less than 10%. One study estimated a higher proportion (69%, 95% CrI 20-85%) with a wide credibility interval [55] (Fig 4). The estimates have large

uncertainty intervals, and the disparate predictions result from differences in the proportion of asymptomatic infections and relative infectiousness of asymptomatic infection.

We included 11 studies providing 16 estimates of the contribution of presymptomatic transmission. The models examined a range of epidemic settings and used different assumptions about the durations and distributions of infection parameters such as incubation period, generation time and serial interval [7, 49, 55, 81, 91, 98, 103, 141-144]. In seven studies, point estimates for the estimated contribution of presymptomatic infection to all SARS-CoV-2 transmission in at least one reported scenario were 40% or greater [7, 81, 91, 98, 103, 142, 144] (Fig 3). In one study that estimated a contribution of <1% [143], the model-fitted serial interval was longer than observed in empirical studies. The credibility of most modelling studies was limited by the absence of external validation and of uncertainty intervals for the estimates cited. (S18 Fig). The estimates from studies that relied on data from different published sources that might not have been compatible were assessed as providing low quality evidence (S5 Table).

Discussion

Summary of main findings

Between-study heterogeneity precluded a reliable estimate of a range of plausible values for the proportion of asymptomatic infections for all included studies, or for screening studies. In studies that identified participants through contact tracing of index cases and outbreak investigations, the proportion of asymptomatic infections was 18% (95% CI 14-24%, prediction interval 3-64%, 40 studies). In 54 studies that identified SARS-CoV-2 infection through screening of defined populations, the prediction interval was 3-94% (IQR 18-59%). The risk ratio for the secondary attack rate from asymptomatic compared with symptomatic infections was 0.43 (95% CI 0.05-3.44, prediction interval 0.0-67.1) and for presymptomatic infections compared with symptomatic infection was 0.71 (95% CI 0.36-1.41, prediction interval 0.10-5.28). In mathematical modelling studies, estimated proportions of all SARS-CoV-2 infections that result from transmission from asymptomatic individuals were mostly below 10%, and from presymptomatic individuals mostly higher than 40%.

Strengths and weaknesses of the living systematic review methods

A strength of the methodology of this review is the transparent reporting, with openly available data and changes over different versions reported in the protocol. Our inclusion criteria attempted to reduce risks of bias and we developed a new tool to address potential biases in the studies included in this review. In contact investigations, we subtracted index cases from the total number of people with SARS-CoV-2 to avoid underestimation of the proportion asymptomatic [14]. We examined heterogeneity in detail and, as a result of the wide prediction interval, we chose not to report an overall summary estimate [19, 146]. A limitation of the methods for this living systematic review is that this update only includes published studies up to 2 February 2021. Although we made extensive efforts to comply with the planned 3-monthly updates, with weekly searches and a continuous process of screening, data extraction and risk of bias assessment, the pace of publications about SARS-CoV-2 exceeds the capacity of our crowd of reviewers [8, 20]. In reviews of observational epidemiological studies, search terms are broad so the number of studies that needs to be screened is high, but the yield of included studies is low. We are in the process of updating our findings and preliminary analyses show that the main findings do not change when including studies published up to April 2021. The four databases that we searched are not comprehensive, but they cover the majority of publications and we do not believe that we have missed studies that would change our conclusions. We have also not considered the possible impact of false negative RT-PCR results, which might be more likely to occur in asymptomatic infections [147] and would underestimate the proportion of asymptomatic infections [148]. We found no published studies of people infected with SARS-CoV-2 variants of concern or of vaccinated people, in line with another systematic review that includes studies published up to April 2021 [14]. Other limitations related to the studies included are discussed below.

Comparison with other reviews and interpretation

The type of studies that provide estimates of the proportion of asymptomatic SARS-CoV-2 infections and heterogeneity between them has changed over the course of the pandemic. In our living systematic review, the prediction interval has widened from 23-37% in studies published up to 25

March 2020 [17], to 3-67% up to June 2020 [10] and 2-89% up to 2 February 2021. We found three systematic reviews, in which authors reported restriction of inclusion to studies with adequate follow-up [9, 11, 14]. In two reviews of studies published up to mid-2020, authors also applied inclusion criteria to reduce the risks of selection bias, with summary estimates of 18% (95% CI 9–26%, I^2 84%, 9 studies) [11] and 23% (95% CI 16–30%, I^2 92%, 21 studies) [9]. In both reviews, many included studies used designs that we defined as contact or outbreak investigations (Fig 1, S2 Table). Sah et al. reviewed studies published up to April 2021 and their subgroup estimate from studies in long-term care facilities, which include many outbreak investigations, was 17.8%, 95% CI 9.7-30.3%, 15 studies [14]. The summary estimates from all these reviews are compatible with our estimate from 40 studies in similar settings (18%, 95% CI 0.14-24%, prediction interval 3-64%, I^2 91%) (S3 Fig).

It may not be possible to obtain a single summary estimate from published literature of the proportion of persistently asymptomatic SARS-CoV-2 infection. Systematic reviews from meta-analysis might be precise, but are likely to be unreliable owing to unacceptably high levels of heterogeneity. In the three largest systematic reviews, other than ours, authors provided overall estimates with narrow confidence intervals [12-14]. I^2 values were 94-99%, describing heterogeneity other than that due to chance, but prediction intervals, which show the extent of all between-study variability were not reported [15]. The prediction intervals that we calculated extended more or less from zero to 100%, making the summary estimates, and any differences in estimates between these studies, uninterpretable. We expected this update to our living systematic review to provide a more precise and less heterogeneous estimate of the proportion of people with asymptomatic SARS-CoV-2 than in the previous version [10]. In particular, we expected that studies that detect SARS-CoV-2 through screening of defined populations and follow up of those infected would be less affected by biases in study methodology [24] and would provide a more accurate estimate of persistently asymptomatic SARS-CoV-2, which should be influenced mainly by properties of the virus and the host response to infection [149]. Information bias, resulting from the way in which asymptomatic status is determined, was the factor most strongly associated with the estimated proportion of

asymptomatic infection in screening studies (Table 2). Studies in which a wide range of possible COVID-19 symptoms are assessed frequently will classify more people as having symptoms than studies with a limited symptom list. Studies based on contact and outbreak investigations might obtain more detailed data about symptoms, resulting in lower estimates of the proportion that is classified as asymptomatic. Selection bias affected studies based on contact and outbreak investigations more than screening studies, however. These studies include people identified mainly through contact tracing and differential inclusion of contacts with symptoms might underestimate the true proportion of asymptomatic SARS-CoV-2. Age might play a role as children appear more likely than adults to have an asymptomatic course of infection, but age was poorly reported in studies included in this review (Table 1).

The analysis of secondary attack rates in this update provides some evidence of lower infectiousness of people with asymptomatic than symptomatic infection, but the small number of studies and wide confidence intervals are compatible with both no difference in transmissibility or higher transmissibility (Fig 2) [128, 129, 139]. The difference in secondary attack rates between asymptomatic and symptomatic index cases in our meta-analysis is smaller than that obtained when groups of studies of asymptomatic index cases and of symptomatic cases are analysed separately [149, 150]. In meta-analyses of two proportions, the direct comparison within studies reduces heterogeneity and is less biased [28]. Since SARS-CoV-2 can be transmitted a few days before the onset of symptoms [151], presymptomatic transmission likely contributes substantially to overall SARS-CoV-2 epidemics. If both the proportion and transmissibility of asymptomatic infection are relatively low, people with asymptomatic SARS-CoV-2 infection should account for a smaller proportion of overall transmission than presymptomatic individuals. This is consistent with the findings of modelling studies in our review.

Implications and unanswered questions

The finding that, in studies of contact and outbreak investigations, a substantial minority of people with SARS-CoV-2 infection remains asymptomatic throughout the course of infection, and that

almost half of all transmission might occur before symptoms develop has already had implications for prevention. When SARS-CoV-2 community transmission levels are high, physical distancing measures and mask-wearing need to be sustained to prevent transmission from close contact with people with asymptomatic and presymptomatic infection. Integration of evidence from epidemiological, clinical and laboratory studies will help to clarify the relative infectiousness of asymptomatic SARS-CoV-2. Studies using viral culture as well as RNA detection are needed since RT-PCR defined viral loads appear to be broadly similar in asymptomatic and symptomatic people [147, 152]. Since late 2020, several SARS-CoV-2 variants of concern have spread internationally [153]. The omicron variant is substantially different from both wild type SARS-Cov-2 and other variants of concern and, owing to high infectiousness and immune evasion, is the dominant variant globally [154]. The clinical characteristics of SARS-CoV-2 infection caused by the omicron variant are not yet known. Future studies and systematic reviews should address evidence about the effects of both variants of concern and vaccines on asymptomatic and presymptomatic SARS-CoV-2. Studying the proportion of asymptomatic infection have become more complicated, however, because of the availability of vaccines that reduce the risk of infection and transmission, and which might also change the clinical presentation of breakthrough infection.

This living systematic review shows the challenges of synthesising evidence from observational epidemiological studies and has implications for the design and reporting of both systematic reviews and the methodology of individual studies. Methodological guidance to refrain from meta-analysis when the variability between studies is extreme is often ignored in favour of summary estimates, which are easy to cite [146]. Heterogeneity in systematic reviews of proportions is a recognised challenge [28, 155]. Part of the heterogeneity arises from the fact that many studies included in this review were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infection. The incomplete descriptions of inclusion criteria, follow-up and definitions of symptom status required in this review made it difficult to assess the risks of bias. To estimate the true proportion of asymptomatic SARS-CoV-2 infections, researchers need to design studies to address this specific

473 research question. Prospective longitudinal studies with methods that minimise selection and
 474 measurement biases, with frequent prospective documentation of symptom status, based on a
 475 defined symptom list [1]. More studies that assess symptom status carefully in index cases and
 476 assess transmission to contacts are needed to quantify the relative transmissibility of SARS-CoV-2
 477 more precisely. Transparent reporting in all studies will help to assess the risks of bias. Without
 478 prospective longitudinal studies with methods that minimise selection and measurement biases,
 479 further updates to this living systematic review are unlikely to provide a reliable summary estimate
 480 of the proportion of asymptomatic infections caused by wild-type SARS-CoV-2.

Figure legends

Figure 1. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by study design. The x-axis displays proportions. Where more than one cluster was reported, clusters are annotated with '[cluster]'. The interquartile range is given below the individual study estimates. The red bar and grey text show the prediction interval.

Figure 2. Forest plot of the secondary attack rate of SARS-CoV-2 infections comparing infections in contacts of asymptomatic and presymptomatic index cases with infections in contacts of symptomatic cases. The RR is on a logarithmic scale. The diamonds show the summary estimate and its 95% confidence interval. CI, confidence interval; E, number of secondary transmission events; N, number of close contacts; RR, risk ratio; Symp. = symptomatic individuals.

Figure 3. Forest plot of proportion ('Prop.') of SARS-CoV-2 infection resulting from asymptomatic or presymptomatic transmission. For studies that report outcomes in multiple settings, these are annotated in brackets. CI, confidence interval; SI, serial interval.

References

1. Meyerowitz EA, Richterman A, Bogoch I, Low N, Cevik M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. *Lancet Infect Dis* 2021;21(6):e163-e9. Epub 2020/12/11. doi: [https://doi.org/10.1016/S1473-3099\(20\)30837-9](https://doi.org/10.1016/S1473-3099(20)30837-9) PubMed PMID: 33301725; PubMed Central PMCID: PMC7834404.
2. Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. *BMJ*. 2020;369:m1375. Epub 2020/04/04. doi: <https://doi.org/10.1136/bmj.m1375>. PubMed PMID: 32241884.
3. Ing AJ, Cocks C, Green JP. COVID-19: in the footsteps of Ernest Shackleton. *Thorax*. 2020;75(8):693-4. doi: <https://doi.org/10.1136/thoraxjnl-2020-215091>.
4. Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. *Nature Communications*. 2020;11(1):5749. doi: <https://doi.org/10.1038/s41467-020-19478-2>.
5. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19 - Studies Needed. *N Engl J Med*. 2020. Epub 2020/02/20. doi: <https://doi.org/10.1056/nejmp2002125>. PubMed PMID: 32074416.
6. Liu Y, Morgenstern C, Kelly J, Lowe R, Jit M. The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. *BMC Med*. 2021;19(1):40. Epub 20210205. doi: <https://doi.org/10.1186/s12916-020-01872-8>. PubMed PMID: 33541353; PubMed Central PMCID: PMC7861967.
7. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dorner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science*. 2020;368(6491). Epub 2020/04/03. doi: <https://doi.org/10.1126/science.abb6936>. PubMed PMID: 32234805; PubMed Central PMCID: PMC7164555.
8. Ipekci AM, Buitrago-Garcia D, Meili KW, Krauer F, Prajapati N, Thapa S, et al. Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus. *BMC Med Res Methodol*. 2021;21(1):50. Epub 20210311. doi: <https://doi.org/10.1186/s12874-021-01244-7>. PubMed PMID: 33706715; PubMed Central PMCID: PMC7948668.
9. Beale S, Hayward A, Shallcross L, Aldridge R, Fragaszy E. A rapid review and meta-analysis of the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections in community settings [version 1; peer review: 1 approved with reservations]. *Wellcome Open Research*. 2020;5(266). doi: <https://doi.org/10.12688/wellcomeopenres.16387.1>.
10. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLOS Medicine*. 2020;17(9):e1003346. doi: <https://doi.org/10.1371/journal.pmed.1003346>.
11. Byambasuren O, Cardona M, Bell K, Clark J, McLaws ML, Glasziou P. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: Systematic review and meta-analysis. *Official Journal of the Association of Medical Microbiology and Infectious Disease Canada*. 2020;Volume 5(Issue 4):pp. 223-34. doi: <https://doi.org/10.3138/jammi-2020-0030>.
12. Chen X, Huang Z, Wang J, Zhao S, Wong MC-S, Chong KC, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. *BMJ Open*. 2021;11(12):e049752. doi: <http://dx.doi.org/10.1136/bmjopen-2021-049752>.
13. Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. *JAMA Network Open*. 2021;4(12):e2137257-e. doi: <https://doi.org/10.1001/jamanetworkopen.2021.37257>.
14. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. *Proc Natl Acad Sci U S*

547 A. 2021;118(34). Epub 2021/08/12. doi: <https://doi.org/10.1073/pnas.2109229118>. PubMed PMID:
548 34376550; PubMed Central PMCID: PMC8403749.

549 15. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*.
550 2011;342:d549.

551 16. Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, et al. Living systematic
552 reviews: an emerging opportunity to narrow the evidence-practice gap. *PLoS Med*.
553 2014;11(2):e1001603. doi: <https://doi.org/10.1371/journal.pmed.1001603>. PubMed PMID:
554 24558353; PubMed Central PMCID: PMC3928029.

555 17. Buitrago-Garcia D, Egli-Gany D, Counotte M, Hossmann S, Imeri H, Salanti G, et al. The role of
556 asymptomatic SARS-CoV-2 infections: rapid living systematic review and meta-analysis. Version 1.
557 medRxiv. 2020. doi: <https://doi.org/10.1101/2020.04.25.20079103>

558 18. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
559 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:
560 <https://doi.org/10.1136/bmj.n71>.

561 19. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis
562 without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ*. 2020;368:l6890. doi:
563 <https://doi.org/10.1136/bmj.l6890>.

564 20. Counotte M, Imeri H, Ipekci M, Low N. COVID-19 living evidence Bern: Institute of Social and
565 Preventive Medicine, University of Bern; 2020 [cited 2020 09.05.2020]. Covid-19 living evidence
566 landing page]. Available from: <https://ispmbern.github.io/covid-19/living-review/>.

567 21. Kahale L, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis A, Sch, nemann H, et al.
568 Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a
569 proposal [version 2; peer review: 1 approved, 1 approved with reservations]. *F1000Research*.
570 2021;10(192). doi: <https://doi.org/10.12688/f1000research.51723.2>.

571 22. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for use in JBI
572 systematic reviews—checklist for case series Adelaide2017 [10.06.2020]. Available from:
573 [https://joannabriggs.org/ebp/critical appraisal tools](https://joannabriggs.org/ebp/critical_appraisal_tools).

574 23. Boyle MH. Guidelines for evaluating prevalence studies. *Evid Based Ment Health*.
575 1998;1(2):37-40.

576 24. Accorsi EK, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, et al. How to detect and
577 reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. *Eur J Epidemiol*.
578 2021;179-96. Epub 2021/02/27. doi: <https://doi.org/10.1007/s10654-021-00727-7>. PubMed PMID:
579 33634345; PubMed Central PMCID: PMC7906244.

580 25. Jaime Caro J, Eddy DM, Kan H, Kaltz C, Patel B, Eldessouki R, et al. Questionnaire to assess
581 relevance and credibility of modeling studies for informing health care decision making: an ISPOR-
582 AMCP-NPC Good Practice Task Force report. *Value Health*. 2014;17(2):174-82. doi:
583 <https://doi.org/10.1016/j.jval.2014.01.003>. PubMed PMID: 24636375.

584 26. Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical
585 tutorial. *Evid Based Ment Health*. 2019;22(4):153-60. Epub 2019/09/30. doi:
586 <https://doi.org/10.1136/ebmental-2019-300117>. PubMed PMID: 31563865.

587 27. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of
588 seven methods. *Stat Med*. 1998;17(8):857-72.

589 28. Schwarzer G, Rücker G. Meta-Analysis of Proportions. *Methods Mol Biol*. 2022;2345:159-72.
590 doi: https://doi.org/10.1007/978-1-0716-1566-9_10. PubMed PMID: 34550590.

591 29. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
592 Transmission of COVID-19. *JAMA*. 2020;54(0):E017. doi: <https://doi.org/10.1001/jama.2020.2565>.

593 30. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia
594 associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a
595 family cluster. *Lancet*. 2020;395(10223):514-23. Epub 2020/01/28. doi:
596 [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9). PubMed PMID: 31986261; PubMed Central
597 PMCID: PMC7159286.

31. Ganyani T, Kremer C, Chen D, Torneri A, Faes C, Wallinga J, et al. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. *Euro Surveill.* 2020;25(17):2020.03.05.20031815. Epub 2020/05/07. doi: <https://doi.org/10.2807/1560-7917.es.2020.25.17.2000257>. PubMed PMID: 32372755; PubMed Central PMCID: PMC7201952.
32. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020;63(5):706-11. Epub 2020/03/09. doi: <https://doi.org/10.1007/s11427-020-1661-4>. PubMed PMID: 32146694; PubMed Central PMCID: PMC7088568.
33. Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, et al. Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. *medRxiv.* 2020. doi: <https://doi.org/10.1016/j.xinn.2020.04.001>.
34. Luo SH, Liu W, Liu ZJ, Zheng XY, Hong CX, Liu ZR, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus. *Chin Med J (Engl).* 2020;133(9):1123-5. Epub 2020/03/10. doi: <https://doi.org/10.1097/cm9.0000000000000798>. PubMed PMID: 32149768.
35. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill.* 2020;25(10). Epub 2020/03/19. doi: <https://doi.org/10.2807/1560-7917.es.2020.25.10.2000180>. PubMed PMID: 32183930; PubMed Central PMCID: PMC7078829.
36. Nishiura H, Kobayashi T, Suzuki A, Jung SM, Hayashi K, Kinoshita R, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int J Infect Dis.* 2020. doi: <https://doi.org/10.1016/j.ijid.2020.03.020>.
37. Qian G, Yang N, Ma AHY, Wang L, Li G, Chen X, et al. A COVID-19 Transmission within a family cluster by presymptomatic infectors in China. *Clin Infect Dis.* 2020. doi: <https://doi.org/10.1093/cid/ciaa316>.
38. Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship 'Diamond Princess' in Japan. *medRxiv.* 2020. doi: <https://doi.org/10.1101/2020.03.18.20038125>.
39. AbdulRahman A, AlAli S, Yaghi O, Shabaan M, Ootom S, Atkin SL, et al. COVID-19 and sickle cell disease in Bahrain. *Int J Infect Dis.* 2020;101:14-6. Epub 2020/09/28. doi: <https://doi.org/10.1016/j.ijid.2020.09.1433>. PubMed PMID: 32980556; PubMed Central PMCID: PMC7833176.
40. Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *JAMA Netw Open.* 2020;3(11):e2029256. Epub 2020/11/20. doi: <https://doi.org/10.1001/jamanetworkopen.2020.29256>. PubMed PMID: 33211113; PubMed Central PMCID: PMC7677755.
41. Al-Qahtani M, AlAli S, AbdulRahman A, Salman Alsayyad A, Ootom S, Atkin SL. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. *Int J Infect Dis.* 2021;102:285-8. Epub 2020/11/07. doi: <https://doi.org/10.1016/j.ijid.2020.10.091>. PubMed PMID: 33157290; PubMed Central PMCID: PMC7607262.
42. Almazeedi S, Al-Youha S, Jamal MH, Al-Haddad M, Al-Muhaini A, Al-Ghimlas F, et al. Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait. *EclinicalMedicine.* 2020;24:100448. Epub 2020/08/09. doi: <https://doi.org/10.1016/j.eclinm.2020.100448>. PubMed PMID: 32766546; PubMed Central PMCID: PMC7335246.
43. Alshahrani MS, Alnimr A, Alnassri S, Alfarag S, Aljehani Y, Alabdali M. Prevalence of the SARS-CoV-2 Infection Among Post-Quarantine Healthcare Workers. *J Multidiscip Healthc.* 2020;13:1927-36. Epub 2020/12/29. doi: <https://doi.org/10.2147/jmdh.s279469>. PubMed PMID: 33363380; PubMed Central PMCID: PMC7752650.
44. Aslam A, Singh J, Robilotti E, Chow K, Bist T, Reidy-Lagunes D, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Surveillance and Exposure in the Perioperative Setting With Universal

- 649 Testing and Personal Protective Equipment Policies. Clin Infect Dis. 2021;73(9):e3013-e8. Epub
650 2020/10/23. doi: <https://doi.org/10.1093/cid/ciaa1607>. PubMed PMID: 33090210; PubMed Central
651 PMCID: PMC7665395.
- 652 45. Balestrini S, Koepp MJ, Gandhi S, Rickman HM, Shin GY, Houlihan CF, et al. Clinical outcomes
653 of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy Behav. 2021;115:107602.
654 Epub 2020/12/07. doi: <https://doi.org/10.1016/j.yebeh.2020.107602>. PubMed PMID: 33279440;
655 PubMed Central PMCID: PMC7643621.
- 656 46. Bender WR, Hirshberg A, Coutifaris P, Acker AL, Srinivas SK. Universal testing for severe
657 acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and
658 symptom development over 2 weeks. Am J Obstet Gynecol MFM. 2020;2(4):100226. Epub
659 2020/09/22. doi: <https://doi.org/10.1016/j.ajogmf.2020.100226>. PubMed PMID: 32954248; PubMed
660 Central PMCID: PMC7485442.
- 661 47. Berghoff AS, Gansterer M, Bathke AC, Trutschnig W, Hungerlander P, Berger JM, et al. SARS-
662 CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19
663 Pandemic. J Clin Oncol. 2020;38(30):3547-54. Epub 2020/08/17. doi:
664 <https://doi.org/10.1200/jco.20.01442>. PubMed PMID: 32795227; PubMed Central PMCID:
665 PMC7571795.
- 666 48. Bogani G, Ditto A, Bosio S, Brusadelli C, Raspagliesi F. Cancer patients affected by COVID-19:
667 Experience from Milan, Lombardy. Gynecol Oncol. 2020;158(2):262-5. Epub 2020/06/15. doi:
668 <https://doi.org/10.1016/j.ygyno.2020.06.161>. PubMed PMID: 32534808; PubMed Central PMCID:
669 PMC7286266.
- 670 49. Bushman M, Worby C, Chang HH, Kraemer MUG, Hanage WP. Transmission of SARS-CoV-2
671 before and after symptom onset: impact of nonpharmaceutical interventions in China. Eur J
672 Epidemiol. 2021;36(4):429-39. Epub 2021/04/22. doi: <https://doi.org/10.1007/s10654-021-00746-4>.
673 PubMed PMID: 33881667; PubMed Central PMCID: PMC8058147.
- 674 50. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, et al. Post-lockdown SARS-CoV-2 nucleic
675 acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020;11(1):5917. Epub
676 2020/11/22. doi: <https://doi.org/10.1038/s41467-020-19802-w>. PubMed PMID: 33219229; PubMed
677 Central PMCID: PMC7679396.
- 678 51. Cariani L, Orena BS, Ambrogi F, Gambazza S, Maraschini A, Dodaro A, et al. Time Length of
679 Negativization and Cycle Threshold Values in 182 Healthcare Workers with Covid-19 in Milan, Italy:
680 An Observational Cohort Study. Int J Environ Res Public Health. 2020;17(15). Epub 2020/07/29. doi:
681 <https://doi.org/10.3390/ijerph17155313>. PubMed PMID: 32718008; PubMed Central PMCID:
682 PMC7432921.
- 683 52. Chamie G, Marquez C, Crawford E, Peng J, Petersen M, Schwab D, et al. Community
684 Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 Disproportionately Affects the
685 Latinx Population During Shelter-in-Place in San Francisco. Clin Infect Dis. 2021;73(Suppl 2):S127-
686 S35. Epub 2020/08/22. doi: <https://doi.org/10.1093/cid/ciaa1234>. PubMed PMID: 32821935;
687 PubMed Central PMCID: PMC7499499.
- 688 53. Corcorran MA, Olin S, Rani G, Nasenbeny K, Constantino-Shor C, Holmes C, et al. Prolonged
689 persistence of PCR-detectable virus during an outbreak of SARS-CoV-2 in an inpatient geriatric
690 psychiatry unit in King County, Washington. Am J Infect Control. 2021;49(3):293-8. Epub 2020/08/23.
691 doi: <https://doi.org/10.1016/j.ajic.2020.08.025>. PubMed PMID: 32827597; PubMed Central PMCID:
692 PMC7438365.
- 693 54. Edelstein M, Obi C, Chand M, Hopkins S, Brown K, Ramsay M. SARS-CoV-2 infection in
694 London, England: changes to community point prevalence around lockdown time, March-May 2020.
695 J Epidemiol Community Health. 2021;75(2):185-8. Epub 2020/10/03. doi:
696 <https://doi.org/10.1136/jech-2020-214730>. PubMed PMID: 33004659; PubMed Central PMCID:
697 PMC7815898.
- 698 55. Emery JC, Russell TW, Liu Y, Hellewell J, Pearson CA, Group CC-W, et al. The contribution of
699 asymptomatic SARS-CoV-2 infections to transmission on the Diamond Princess cruise ship. Elife.

- 2020;9. Epub 2020/08/25. doi: <https://doi.org/10.7554/elife.58699>. PubMed PMID: 32831176; PubMed Central PMCID: PMC7527238.
56. Eythorsson E, Helgason D, Ingvarsson RF, Bjornsson HK, Olafsdottir LB, Bjarnadottir V, et al. Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. *BMJ*. 2020;371:m4529. Epub 2020/12/04. doi: <https://doi.org/10.1136/bmj.m4529>. PubMed PMID: 33268329; PubMed Central PMCID: PMC7708618.
57. Ferreira VH, Chruscinski A, Kulasingam V, Pugh TJ, Dus T, Wouters B, et al. Prospective observational study and serosurvey of SARS-CoV-2 infection in asymptomatic healthcare workers at a Canadian tertiary care center. *PLoS One*. 2021;16(2):e0247258. Epub 2021/02/17. doi: <https://doi.org/10.1371/journal.pone.0247258>. PubMed PMID: 33592074; PubMed Central PMCID: PMC7886177.
58. Ghinai I, Davis ES, Mayer S, Toews KA, Huggett TD, Snow-Hill N, et al. Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Homeless Shelters in Chicago, Illinois-March-May, 2020. *Open Forum Infect Dis*. 2020;7(11):ofaa477. Epub 2020/12/03. doi: <https://doi.org/10.1093/ofid/ofaa477>. PubMed PMID: 33263069; PubMed Central PMCID: PMC7665740.
59. Green R, Tulloch JSP, Tunnah C, Coffey E, Lawrenson K, Fox A, et al. COVID-19 testing in outbreak-free care homes: what are the public health benefits? *J Hosp Infect*. 2021;111:89-95. Epub 2021/01/17. doi: <https://doi.org/10.1016/j.jhin.2020.12.024>. PubMed PMID: 33453349; PubMed Central PMCID: PMC7837210.
60. Grijalva CG, Rolfes MA, Zhu Y, McLean HQ, Hanson KE, Belongia EA, et al. Transmission of SARS-CoV-2 Infections in Households - Tennessee and Wisconsin, April-September 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(44):1631-4. Epub 2020/11/06. doi: <http://dx.doi.org/10.15585/mmwr.mm6944e1>. PubMed PMID: 33151916; PubMed Central PMCID: PMC7643897.
61. Han X, Wei X, Alwalid O, Cao Y, Li Y, Wang L, et al. Severe Acute Respiratory Syndrome Coronavirus 2 among Asymptomatic Workers Screened for Work Resumption, China. *Emerg Infect Dis*. 2020;26(9). Epub 2020/06/20. doi: <https://doi.org/10.3201/eid2609.201848>. PubMed PMID: 32553070; PubMed Central PMCID: PMC7454110.
62. Harada S, Uno S, Ando T, Iida M, Takano Y, Ishibashi Y, et al. Control of a Nosocomial Outbreak of COVID-19 in a University Hospital. *Open Forum Infect Dis*. 2020;7(12):ofaa512. Epub 2020/12/18. doi: <https://doi.org/10.1093/ofid/ofaa512>. PubMed PMID: 33330740; PubMed Central PMCID: PMC7665726.
63. Hcini N, Maamri F, Picone O, Carod JF, Lambert V, Mathieu M, et al. Maternal, fetal and neonatal outcomes of large series of SARS-CoV-2 positive pregnancies in peripartum period: A single-center prospective comparative study. *Eur J Obstet Gynecol Reprod Biol*. 2021;257:11-8. Epub 2020/12/15. doi: <https://doi.org/10.1016/j.ejogrb.2020.11.068>. PubMed PMID: 33310656; PubMed Central PMCID: PMC7705341.
64. Hogan CA, Gombar S, Wang H, Roltgen K, Shi RZ, Holubar M, et al. Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis*. 2021;27(1). Epub 2020/12/02. doi: <https://doi.org/10.3201/eid2701.203892>. PubMed PMID: 33256889; PubMed Central PMCID: PMC7774535.
65. Hurst JH, Heston SM, Chambers HN, Cunningham HM, Price MJ, Suarez L, et al. SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. *medRxiv*. 2020. Epub 2020/09/11. doi: <https://doi.org/10.1101/2020.08.18.20166835>. PubMed PMID: 32908992; PubMed Central PMCID: PMC7480040.
66. Jones A, Fialkowski V, Prinzing L, Trites J, Kelso P, Levine M. Assessment of Day-7 Postexposure Testing of Asymptomatic Contacts of COVID-19 Patients to Evaluate Early Release from Quarantine - Vermont, May-November 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(1):12-3. Epub 2021/01/08. doi: <http://dx.doi.org/10.15585/mmwr.mm7001a3>. PubMed PMID: 33411700; PubMed Central PMCID: PMC7790157.

751 67. Kasper MR, Geibe JR, Sears CL, Riegodedios AJ, Luse T, Von Thun AM, et al. An Outbreak of
752 Covid-19 on an Aircraft Carrier. *N Engl J Med.* 2020;383(25):2417-26. Epub 2020/11/12. doi:
753 <https://doi.org/10.1056/nejmoa2019375>. PubMed PMID: 33176077; PubMed Central PMCID:
754 PMC7675688.

755 68. Kennelly SP, Dyer AH, Noonan C, Martin R, Kennelly SM, Martin A, et al. Asymptomatic
756 carriage rates and case fatality of SARS-CoV-2 infection in residents and staff in Irish nursing homes.
757 *Age Ageing.* 2021;50(1):49-54. Epub 2020/09/29. doi: <https://doi.org/10.1093/ageing/afaa220>.
758 PubMed PMID: 32986806; PubMed Central PMCID: PMC7543256.

759 69. Khondaker T, Qader MA, Gosh K, Chowdhury GN, Ferdous T, Afroz S, et al. Clinical Profile and
760 Outcome of COVID -19 in Children with Pre-Existing Renal Disease. *Journal of Pediatric Nephrology.*
761 2020;9(1):1-6. doi: <https://doi.org/10.22037/jpn.v9i1.33008>.

762 70. Kirshblum SC, DeLauter G, Lopreiato MC, Pomeranz B, Dawson A, Hammerman S, et al.
763 Screening Testing for SARS-CoV-2 upon Admission to Rehabilitation Hospitals in a High COVID-19
764 Prevalence Community. *PM R.* 2020;12(10):1009-14. Epub 2020/07/24. doi:
765 <https://doi.org/10.1002/pmrj.12454>. PubMed PMID: 32700434; PubMed Central PMCID:
766 PMC7404891.

767 71. Kittang BR, Hofacker SV, Solheim SP, Kruger K, Loland KK, Jansen K. Outbreak of COVID-19 at
768 three nursing homes in Bergen. *Tidsskr Nor Laegeforen.* 2020;140(11). Epub 2020/08/21. doi:
769 <https://doi.org/10.4045/tidsskr.20.0405>. PubMed PMID: 32815356.

770 72. Kutsuna S, Suzuki T, Hayakawa K, Tsuzuki S, Asai Y, Suzuki T, et al. SARS-CoV-2 Screening Test
771 for Japanese Returnees From Wuhan, China, January 2020. *Open Forum Infect Dis.*
772 2020;7(7):ofaa243. Epub 2020/08/06. doi: <https://doi.org/10.1093/ofid/ofaa243>. PubMed PMID:
773 32754627; PubMed Central PMCID: PMC7337761.

774 73. Ladhani SN, Jeffery-Smith A, Patel M, Janarthanan R, Fok J, Crawley-Boevey E, et al. High
775 prevalence of SARS-CoV-2 antibodies in care homes affected by COVID-19: Prospective cohort study,
776 England. *EclinicalMedicine.* 2020;28:100597. Epub 2020/11/12. doi:
777 <https://doi.org/10.1016/j.eclinm.2020.100597>. PubMed PMID: 33173854; PubMed Central PMCID:
778 PMC7644437.

779 74. Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and clinical
780 characteristics of coronavirus disease 2019 in Daegu, South Korea. *Int J Infect Dis.* 2020;98:462-6.
781 Epub 2020/07/24. doi: <https://doi.org/10.1016/j.ijid.2020.07.017>. PubMed PMID: 32702415;
782 PubMed Central PMCID: PMC7371586.

783 75. Letizia AG, Ramos I, Obla A, Goforth C, Weir DL, Ge Y, et al. SARS-CoV-2 Transmission among
784 Marine Recruits during Quarantine. *N Engl J Med.* 2020;383(25):2407-16. Epub 2020/11/12. doi:
785 <https://doi.org/10.1056/nejmoa2029717>. PubMed PMID: 33176093; PubMed Central PMCID:
786 PMC7675690.

787 76. Mahajan NN, Kesarwani SN, Shinde SS, Nayak A, Modi DN, Mahale SD, et al. Co-infection of
788 malaria and dengue in pregnant women with SARS-CoV-2. *Int J Gynaecol Obstet.* 2020;151(3):459-
789 62. Epub 2020/10/23. doi: <https://doi.org/10.1002/ijgo.13415>. PubMed PMID: 33090458; PubMed
790 Central PMCID: PMC7611276.

791 77. Malagon-Rojas J, Gomez-Rendon C, Parra EL, Almentero J, Palma R, Lopez R, et al. SARS-CoV-
792 2 and RT-PCR in asymptomatic patients: Results of a cohort of workers at El Dorado International
793 Airport in Bogota, 2020. *Biomedica.* 2020;40(Supl. 2):166-72. Epub 2020/11/06. doi:
794 <https://doi.org/10.7705/biomedica.5802>. PubMed PMID: 33152200; PubMed Central PMCID:
795 PMC7676845.

796 78. Marossy A, Rakowicz S, Bhan A, Noon S, Rees A, Virk M, et al. A Study of Universal Severe
797 Acute Respiratory Syndrome Coronavirus 2 RNA Testing Among Residents and Staff in a Large Group
798 of Care Homes in South London. *J Infect Dis.* 2021;223(3):381-8. Epub 2020/09/06. doi:
799 <https://doi.org/10.1093/infdis/jiaa565>. PubMed PMID: 32889532; PubMed Central PMCID:
800 PMC7499645.

79. Meyers KJ, Dillman B, Williams C, Jiang J, Clifford N, Miller JL, et al. Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study. *J Med Virol*. 2021;93(5):2925-31. Epub 2021/01/20. doi: <https://doi.org/10.1002/jmv.26810>. PubMed PMID: 33463731; PubMed Central PMCID: PMC8014630.
80. Migisha R, Kwesiga B, Mirembe BB, Amanya G, Kabwama SN, Kadobera D, et al. Early cases of SARS-CoV-2 infection in Uganda: epidemiology and lessons learned from risk-based testing approaches - March-April 2020. *Global Health*. 2020;16(1):114. Epub 2020/11/27. doi: <https://doi.org/10.1186/s12992-020-00643-7>. PubMed PMID: 33239041; PubMed Central PMCID: PMC7686950.
81. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The implications of silent transmission for the control of COVID-19 outbreaks. *Proc Natl Acad Sci U S A*. 2020;117(30):17513-5. Epub 2020/07/08. doi: <https://doi.org/10.1073/pnas.2008373117>. PubMed PMID: 32632012; PubMed Central PMCID: PMC7395516.
82. Njuguna H, Wallace M, Simonson S, Tobolowsky FA, James AE, Bordelon K, et al. Serial Laboratory Testing for SARS-CoV-2 Infection Among Incarcerated and Detained Persons in a Correctional and Detention Facility - Louisiana, April-May 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(26):836-40. Epub 2020/07/03. doi: <https://doi.org/10.15585/mmwr.mm6926e2>. PubMed PMID: 32614816; PubMed Central PMCID: PMC7332096.
83. Park JH, Jang JH, Lee K, Yoo SJ, Shin H. COVID-19 Outbreak and Presymptomatic Transmission in Pilgrim Travelers Who Returned to Korea from Israel. *J Korean Med Sci*. 2020;35(48):e424. Epub 2020/12/15. doi: <https://doi.org/10.3346/jkms.2020.35.e424>. PubMed PMID: 33316860; PubMed Central PMCID: PMC7735917.
84. Patel MC, Chaisson LH, Borgetti S, Burdsall D, Chugh RK, Hoff CR, et al. Asymptomatic SARS-CoV-2 Infection and COVID-19 Mortality During an Outbreak Investigation in a Skilled Nursing Facility. *Clin Infect Dis*. 2020;71(11):2920-6. Epub 2020/06/18. doi: <https://doi.org/10.1093/cid/ciaa763>. PubMed PMID: 32548628; PubMed Central PMCID: PMC7337684.
85. Pavli A, Smeti P, Papadima K, Andreopoulou A, Hadjianastasiou S, Triantafyllou E, et al. A cluster of COVID-19 in pilgrims to Israel. *J Travel Med*. 2020;27(5). Epub 2020/06/26. doi: <https://doi.org/10.1093/jtm/taaa102>. PubMed PMID: 32584403; PubMed Central PMCID: PMC7337872.
86. Pirnay JP, Selhorst P, Cochez C, Petrillo M, Claes V, Van der Beken Y, et al. Study of a SARS-CoV-2 Outbreak in a Belgian Military Education and Training Center in Maradi, Niger. *Viruses*. 2020;12(9). Epub 2020/09/02. doi: <https://doi.org/10.3390/v12090949>. PubMed PMID: 32867108; PubMed Central PMCID: PMC7552053.
87. Pizarro-Sanchez MS, Avello A, Mas-Fontao S, Stock da Cunha T, Goma-Garces E, Pereira M, et al. Clinical Features of Asymptomatic SARS-CoV-2 Infection in Hemodialysis Patients. *Kidney Blood Press Res*. 2021;46(1):126-34. Epub 2021/01/28. doi: <https://doi.org/10.1159/000512535>. PubMed PMID: 33503627; PubMed Central PMCID: PMC7900451.
88. Plucinski MM, Wallace M, Uehara A, Kurbatova EV, Tobolowsky FA, Schneider ZD, et al. Coronavirus Disease 2019 (COVID-19) in Americans Aboard the Diamond Princess Cruise Ship. *Clin Infect Dis*. 2021;72(10):e448-e57. Epub 2020/08/14. doi: <https://doi.org/10.1093/cid/ciaa1180>. PubMed PMID: 32785683; PubMed Central PMCID: PMC7454359.
89. Rauch JN, Valois E, Ponce-Rojas JC, Aralis Z, Lach RS, Zappa F, et al. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Screening Using Reverse Transcriptase-Quantitative Polymerase Chain Reaction or CRISPR-Based Assays in Asymptomatic College Students. *JAMA Netw Open*. 2021;4(2):e2037129. Epub 2021/02/12. doi: <https://doi.org/10.1001/jamanetworkopen.2020.37129>. PubMed PMID: 33570576; PubMed Central PMCID: PMC7879237.
90. Redditt V, Wright V, Rashid M, Male R, Bogoch I. Outbreak of SARS-CoV-2 infection at a large refugee shelter in Toronto, April 2020: a clinical and epidemiologic descriptive analysis. *CMAJ Open*.

- 2020;8(4):E819-E24. Epub 2020/12/10. doi: <https://doi.org/10.9778/cmajo.20200165>. PubMed PMID: 33293331; PubMed Central PMCID: PMC7743908.
91. Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, et al. Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in China. *Influenza Other Respir Viruses*. 2021;15(1):19-26. Epub 2020/08/09. doi: <https://doi.org/10.1111/irv.12787>. PubMed PMID: 32767657; PubMed Central PMCID: PMC7436222.
92. Romao VC, Oliveira-Ramos F, Cruz-Machado AR, Martins P, Barreira S, Silva-Dinis J, et al. A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. *Front Med (Lausanne)*. 2020;7:576162. Epub 2020/10/27. doi: <https://doi.org/10.3389/fmed.2020.576162>. PubMed PMID: 33102507; PubMed Central PMCID: PMC7546334.
93. Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective control of SARS-CoV-2 transmission in Wanzhou, China. *Nat Med*. 2021;27(1):86-93. Epub 20201130. doi: <https://doi.org/10.1038/s41591-020-01178-5>. PubMed PMID: 33257893.
94. Shi SM, Bakaev I, Chen H, Trivison TG, Berry SD. Risk Factors, Presentation, and Course of Coronavirus Disease 2019 in a Large, Academic Long-Term Care Facility. *J Am Med Dir Assoc*. 2020;21(10):1378-83.e1. Epub 20200825. doi: <https://doi.org/10.1016/j.jamda.2020.08.027>. PubMed PMID: 32981664; PubMed Central PMCID: PMC7447263.
95. Smith E, Aldus CF, Brainard J, Dunham S, Hunter PR, Steel N, et al. Testing for SARS-CoV-2 in care home staff and residents in English care homes: A service evaluation. *medRxiv*. 2020.
96. Starling A, White E, Showell D, Wyllie D, Kapadia S, Balakrishnan R. Whole Care Home Testing for Covid-19 in a Local Authority Area in the United Kingdom. *medRxiv*. 2020.
97. Stock AD, Bader ER, Cezayirli P, Inocencio J, Chalmers SA, Yassari R, et al. COVID-19 Infection Among Healthcare Workers: Serological Findings Supporting Routine Testing. *Front Med (Lausanne)*. 2020;7:471. Epub 2020/09/26. doi: <https://doi.org/10.3389/fmed.2020.00471>. PubMed PMID: 32974370; PubMed Central PMCID: PMC7472984.
98. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2. *Science*. 2021;371(6526). Epub 2020/11/26. doi: <https://doi.org/10.1126/science.abe2424>. PubMed PMID: 33234698; PubMed Central PMCID: PMC7857413.
99. Tan-Loh J, Cheong BMK. A descriptive analysis of clinical characteristics of COVID-19 among healthcare workers in a district specialist hospital. *Med J Malaysia*. 2021;76(1):24-8. Epub 2021/01/30. PubMed PMID: 33510104.
100. Tanacan A, Erol SA, Turgay B, Anuk AT, Secen EI, Yegin GF, et al. The rate of SARS-CoV-2 positivity in asymptomatic pregnant women admitted to hospital for delivery: Experience of a pandemic center in Turkey. *Eur J Obstet Gynecol Reprod Biol*. 2020;253:31-4. Epub 2020/08/09. doi: <https://doi.org/10.1016/j.ejogrb.2020.07.051>. PubMed PMID: 32763728; PubMed Central PMCID: PMC7390745.
101. Taylor J, Carter RJ, Lehnertz N, Kazazian L, Sullivan M, Wang X, et al. Serial Testing for SARS-CoV-2 and Virus Whole Genome Sequencing Inform Infection Risk at Two Skilled Nursing Facilities with COVID-19 Outbreaks - Minnesota, April-June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(37):1288-95. Epub 2020/09/24. doi: <https://doi.org/10.15585/mmwr.mm6937a3>. PubMed PMID: 32966272; PubMed Central PMCID: PMC7498172.
102. Theuring S, Thielecke M, van Loon W, Hommes F, Hulso C, von der Haar A, et al. SARS-CoV-2 infection and transmission in school settings during the second COVID-19 wave: a cross-sectional study, Berlin, Germany, November 2020. *Euro Surveill*. 2021;26(34). Epub 2021/08/28. doi: <https://doi.org/10.2807/1560-7917.es.2021.26.34.2100184>. PubMed PMID: 34448448; PubMed Central PMCID: PMC8393892.
103. Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, et al. Evidence for transmission of COVID-19 prior to symptom onset. *Elife*. 2020;9. Epub 2020/06/23. doi:

- 902 <https://doi.org/10.7554/elife.57149>. PubMed PMID: 32568070; PubMed Central PMCID:
903 PMC7386904.
- 904 104. van Buul LW, van den Besselaar JH, Koene F, Buurman BM, Hertogh C, Group** C-N-S, et al.
905 Asymptomatic Cases and Limited Transmission of SARS-CoV-2 in Residents and Healthcare Workers
906 in Three Dutch Nursing Homes. *Gerontol Geriatr Med*. 2020;6:2333721420982800. Epub
907 2021/01/12. doi: <https://doi.org/10.1177/2333721420982800>. PubMed PMID: 33426178; PubMed
908 Central PMCID: PMC7756037.
- 909 105. van den Besselaar JH, Sikkema RS, Koene F, van Buul LW, Oude Munnink BB, Frenay I, et al.
910 Are presymptomatic SARS-CoV-2 infections in nursing home residents unrecognised symptomatic
911 infections? Sequence and metadata from weekly testing in an extensive nursing home outbreak. *Age*
912 *Ageing*. 2021;50(5):1454-63. Epub 2021/05/09. doi: <https://doi.org/10.1093/ageing/afab081>.
913 PubMed PMID: 33963830; PubMed Central PMCID: PMC8136016.
- 914 106. Varnell C, Jr., Harshman LA, Smith L, Liu C, Chen S, Al-Akash S, et al. COVID-19 in pediatric
915 kidney transplantation: The Improving Renal Outcomes Collaborative. *Am J Transplant*.
916 2021;21(8):2740-8. Epub 2021/01/17. doi: <https://doi.org/10.1111/ajt.16501>. PubMed PMID:
917 33452854; PubMed Central PMCID: PMC8013281.
- 918 107. Vinuela MC, De Leon-Luis JA, Alonso R, Catalan P, Lizarraga S, Munoz P, et al. SARS-CoV-2
919 screening of asymptomatic women admitted for delivery must be performed with a combination of
920 microbiological techniques: an observational study. *Rev Esp Quimioter*. 2020;33(6):415-21. Epub
921 2020/09/19. doi: <https://doi.org/10.37201/req/088.2020>. PubMed PMID: 32945157; PubMed
922 Central PMCID: PMC7712338.
- 923 108. Wadhwa A, Fisher KA, Silver R, Koh M, Arons MM, Miller DA, et al. Identification of
924 Presymptomatic and Asymptomatic Cases Using Cohort-Based Testing Approaches at a Large
925 Correctional Facility-Chicago, Illinois, USA, May 2020. *Clin Infect Dis*. 2021;72(5):e128-e35. Epub
926 2020/12/04. doi: <https://doi.org/10.1093/cid/ciaa1802>. PubMed PMID: 33270101; PubMed Central
927 PMCID: PMC7799274.
- 928 109. White EM, Santostefano CM, Feifer RA, Kosar CM, Blackman C, Gravenstein S, et al.
929 Asymptomatic and Presymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection
930 Rates in a Multistate Sample of Skilled Nursing Facilities. *JAMA Intern Med*. 2020;180(12):1709-11.
931 Epub 2020/10/20. doi: <https://doi.org/10.1001/jamainternmed.2020.5664>. PubMed PMID:
932 33074318; PubMed Central PMCID: PMC7573793.
- 933 110. Wi YM, Lim SJ, Kim SH, Lim S, Lee SJ, Ryu BH, et al. Response System for and Epidemiological
934 Features of COVID-19 in Gyeongsangnam-do Province in South Korea. *Clin Infect Dis*.
935 2021;72(4):661-7. Epub 2020/07/17. doi: <https://doi.org/10.1093/cid/ciaa967>. PubMed PMID:
936 32672789; PubMed Central PMCID: PMC7454481.
- 937 111. Yau K, Muller MP, Lin M, Siddiqui N, Neskovic S, Shokar G, et al. COVID-19 Outbreak in an
938 Urban Hemodialysis Unit. *Am J Kidney Dis*. 2020;76(5):690-5 e1. Epub 2020/07/19. doi:
939 <https://doi.org/10.1053/j.ajkd.2020.07.001>. PubMed PMID: 32681983; PubMed Central PMCID:
940 PMC7362862.
- 941 112. Yousaf AR, Duca LM, Chu V, Reses HE, Fajans M, Rabold EM, et al. A Prospective Cohort
942 Study in Nonhospitalized Household Contacts With Severe Acute Respiratory Syndrome Coronavirus
943 2 Infection: Symptom Profiles and Symptom Change Over Time. *Clin Infect Dis*. 2021;73(7):e1841-e9.
944 Epub 2020/07/29. doi: <https://doi.org/10.1093/cid/ciaa1072>. PubMed PMID: 32719874; PubMed
945 Central PMCID: PMC7454397.
- 946 113. Andrikopoulou M, Madden N, Wen T, Aubey JJ, Aziz A, Baptiste CD, et al. Symptoms and
947 Critical Illness Among Obstetric Patients With Coronavirus Disease 2019 (COVID-19) Infection. *Obstet*
948 *Gynecol*. 2020;136(2):291-9. Epub 2020/05/28. doi:
949 <https://doi.org/10.1097/aog.0000000000003996>. PubMed PMID: 32459701.
- 950 114. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic
951 SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *N Engl J Med*.

2020;382(22):2081-90. Epub 2020/04/25. doi: <https://doi.org/10.1056/NEJMoa2008457>. PubMed PMID: 32329971; PubMed Central PMCID: PMC7200056.

115. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis.* 2020;20(8):911-9. Epub 2020/05/01. doi: [https://doi.org/10.1016/s1473-3099\(20\)30287-5](https://doi.org/10.1016/s1473-3099(20)30287-5). PubMed PMID: 32353347; PubMed Central PMCID: PMC7185944.

116. Bohmer MM, Buchholz U, Corman VM, Hoch M, Katz K, Marosevic DV, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis.* 2020;20(8):920-8. Epub 2020/05/19. doi: [https://doi.org/10.1016/s1473-3099\(20\)30314-5](https://doi.org/10.1016/s1473-3099(20)30314-5). PubMed PMID: 32422201; PubMed Central PMCID: PMC7228725.

117. Brandstetter S, Roth S, Harner S, Buntrock-Dopke H, Toncheva AA, Borchers N, et al. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak. *Pediatr Allergy Immunol.* 2020;31(7):841-7. Epub 2020/05/16. doi: <https://doi.org/10.1111/pai.13278>. PubMed PMID: 32413201.

118. Chang L, Zhao L, Gong H, Wang L, Wang L. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations. *Emerg Infect Dis.* 2020;26(7):1631-3. Epub 2020/04/04. doi: <https://doi.org/10.3201/eid2607.200839>. PubMed PMID: 32243255; PubMed Central PMCID: PMC7323524.

119. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern Med.* 2020;180(9):1156-63. Epub 2020/05/02. doi: <https://doi.org/10.1001/jamainternmed.2020.2020>. PubMed PMID: 32356867; PubMed Central PMCID: PMC7195694.

120. Danis K, Epaulard O, Benet T, Gaymard A, Campoy S, Bothelo-Nevers E, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. *Clin Infect Dis.* 2020. Epub 2020/04/12. doi: <https://doi.org/10.1093/cid/ciaa424>. PubMed PMID: 32277759; PubMed Central PMCID: PMC7184384.

121. Dora AV, Winnett A, Jatt LP, Davar K, Watanabe M, Sohn L, et al. Universal and Serial Laboratory Testing for SARS-CoV-2 at a Long-Term Care Skilled Nursing Facility for Veterans - Los Angeles, California, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(21):651-5. Epub 2020/05/29. doi: <https://doi.org/10.15585/mmwr.mm6921e1>. PubMed PMID: 32463809; PubMed Central PMCID: PMC7269604.

122. Graham NSN, Junghans C, Downes R, Sendall C, Lai H, McKirdy A, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. *J Infect.* 2020;81(3):411-9. Epub 2020/06/07. doi: <https://doi.org/10.1016/j.jinf.2020.05.073>. PubMed PMID: 32504743; PubMed Central PMCID: PMC7836316.

123. Hijnen D, Marzano AV, Eyerich K, GeurtsvanKessel C, Gimenez-Arnau AM, Joly P, et al. SARS-CoV-2 Transmission from Presymptomatic Meeting Attendee, Germany. *Emerg Infect Dis.* 2020;26(8):1935-7. Epub 2020/05/12. doi: <https://doi.org/10.3201/eid2608.201235>. PubMed PMID: 32392125; PubMed Central PMCID: PMC7392453.

124. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *N Engl J Med.* 2020;382(13):1278-80. Epub 2020/02/19. doi: <https://doi.org/10.1056/nejmc2001899>. PubMed PMID: 32069388; PubMed Central PMCID: PMC7121749.

125. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature.* 2020;584(7821):425-9. Epub 2020/07/01. doi: <https://doi.org/10.1038/s41586-020-2488-1>. PubMed PMID: 32604404.

126. Lombardi A, Consonni D, Carugno M, Bozzi G, Mangioni D, Muscatello A, et al. Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy. *Clin Microbiol Infect.* 2020;26(10):1413 e9- e13. Epub 2020/06/23.

doi: <https://doi.org/10.1016/j.cmi.2020.06.013>. PubMed PMID: 32569835; PubMed Central PMCID: PMC7305713.

127. London V, McLaren R, Jr., Atallah F, Cepeda C, McCalla S, Fisher N, et al. The Relationship between Status at Presentation and Outcomes among Pregnant Women with COVID-19. *Am J Perinatol.* 2020;37(10):991-4. Epub 2020/05/20. doi: <https://doi.org/10.1055/s-0040-1712164>. PubMed PMID: 32428964; PubMed Central PMCID: PMC7416203.

128. Luo L, Liu D, Liao X, Wu X, Jing Q, Zheng J, et al. Contact Settings and Risk for Transmission in 3410 Close Contacts of Patients With COVID-19 in Guangzhou, China : A Prospective Cohort Study. *Ann Intern Med.* 2020;173(11):879-87. Epub 2020/08/14. doi: <https://doi.org/10.7326/m20-2671>. PubMed PMID: 32790510; PubMed Central PMCID: PMC7506769.

129. Park SY, Kim YM, Yi S, Lee S, Na BJ, Kim CB, et al. Coronavirus Disease Outbreak in Call Center, South Korea. *Emerg Infect Dis.* 2020;26(8):1666-70. Epub 2020/04/24. doi: <https://doi.org/10.3201/eid2608.201274>. PubMed PMID: 32324530; PubMed Central PMCID: PMC7392450.

130. Pham TQ, Rabaa MA, Duong LH, Dang TQ, Tran QD, Quach HL, et al. The first 100 days of SARS-CoV-2 control in Vietnam. *medRxiv.* 2020. doi: <https://doi.org/10.1101/2020.05.12.20099242>.

131. Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife.* 2020;9. Epub 2020/05/12. doi: <https://doi.org/10.7554/elife.58728>. PubMed PMID: 32392129.

132. Schwierzeck V, König JC, Kuhn J, Mellmann A, Correa-Martinez CL, Omran H, et al. First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis Unit. *Clin Infect Dis.* 2021;72(2):265-70. Epub 2021/01/28. doi: <https://doi.org/10.1093/cid/ciaa491>. PubMed PMID: 33501962; PubMed Central PMCID: PMC7197625.

133. Tian S, Wu M, Chang Z, Wang Y, Zhou G, Zhang W, et al. Epidemiological investigation and intergenerational clinical characteristics of 24 coronavirus disease patients associated with a supermarket cluster: a retrospective study. *BMC Public Health.* 2021;21(1):647. Epub 2021/04/03. doi: <https://doi.org/10.1186/s12889-021-10713-z>. PubMed PMID: 33794836; PubMed Central PMCID: PMC8016429.

134. Treibel TA, Manisty C, Burton M, McKnight NA, Lambourne J, Augusto JB, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *Lancet.* 2020. doi: [https://doi.org/10.1016/s0140-6736\(20\)31100-4](https://doi.org/10.1016/s0140-6736(20)31100-4).

135. Wong J, Abdul Aziz ABZ, Chaw L, Mahamud A, Griffith MM, Ying-Ru LO, et al. High proportion of asymptomatic and presymptomatic COVID-19 infections in travelers and returning residents to Brunei. *J Travel Med.* 2020. doi: <https://doi.org/10.1093/jtm/taaa066>.

136. Wu J, Huang Y, Tu C, Bi C, Chen Z, Luo L, et al. Household Transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin Infect Dis.* 2020;71(16):2099-108. Epub 2020/05/12. doi: <https://doi.org/10.1093/cid/ciaa557>. PubMed PMID: 32392331; PubMed Central PMCID: PMC7239243.

137. Yang N, Shen Y, Shi C, Ma AHY, Zhang X, Jian X, et al. In-flight transmission cluster of COVID-19: a retrospective case series. *Infect Dis (Lond).* 2020;52(12):891-901. Epub 2020/08/01. doi: <https://doi.org/10.1080/23744235.2020.1800814>. PubMed PMID: 32735163.

138. Zhang W, Cheng W, Luo L, Ma Y, Xu C, Qin P, et al. Secondary Transmission of Coronavirus Disease from Presymptomatic Persons, China. *Emerg Infect Dis.* 2020;26(8):1924-6. Epub 2020/05/27. doi: <https://doi.org/10.3201/eid2608.201142>. PubMed PMID: 32453686; PubMed Central PMCID: PMC7392433.

139. Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of SARS-CoV-2 Transmission in Different Settings, Brunei. *Emerg Infect Dis.* 2020;26(11):2598-606. Epub 2020/10/10. doi: <https://doi.org/10.3201/eid2611.202263>. PubMed PMID: 33035448; PubMed Central PMCID: PMC7588541.

140. Luo L, Liu D, Liao X-l, Wu X-b, Jing Q-l, Zheng J-z, et al. Modes of contact and risk of transmission in COVID-19 among close contacts. *bioRxiv*. 2020. doi: <https://doi.org/10.1101/2020.03.24.20042606>.
141. Chun JY, Baek G, Kim Y. Transmission onset distribution of COVID-19. *Int J Infect Dis*. 2020;99:403-7. Epub 2020/08/11. doi: <https://doi.org/10.1016/j.ijid.2020.07.075>. PubMed PMID: 32771633; PubMed Central PMCID: PMC7409940.
142. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*. 2020;26(5):672-5. Epub 2020/04/17. doi: <https://doi.org/10.1038/s41591-020-0869-5>. PubMed PMID: 32296168.
143. Peak CM, Kahn R, Grad YH, Childs LM, Li R, Lipsitch M, et al. Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study. *Lancet Infect Dis*. 2020;20(9):1025-33. Epub 2020/05/24. doi: [https://doi.org/10.1016/s1473-3099\(20\)30361-3](https://doi.org/10.1016/s1473-3099(20)30361-3). PubMed PMID: 32445710; PubMed Central PMCID: PMC7239635.
144. Zhang W. Estimating the presymptomatic transmission of COVID19 using incubation period and serial interval data. *bioRxiv*. 2020. doi: <https://doi.org/10.1101/2020.04.02.20051318>.
145. Thai PQ, Rabaa MA, Luong DH, Tan DQ, Quang TD, Quach HL, et al. The First 100 Days of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Control in Vietnam. *Clin Infect Dis*. 2021;72(9):e334-e42. Epub 2020/08/02. doi: <https://doi.org/10.1093/cid/ciaa1130>. PubMed PMID: 32738143; PubMed Central PMCID: PMC7454342.
146. McKenzie JE, Brennan SE. Synthesizing and presenting findings using other methods. *Cochrane Handbook for Systematic Reviews of Interventions* 2019. p. 321-47.
147. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clin Infect Dis*. 2020. doi: 10.1093/cid/ciaa711.
148. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. *Ann Intern Med*. 2020. Epub 2020/05/19. doi: <https://doi.org/10.7326/M20-1495>. PubMed PMID: 32422057; PubMed Central PMCID: PMC7240870.
149. Qiu X, Nergiz AI, Maraolo AE, Bogoch, II, Low N, Cevik M. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. *Clin Microbiol Infect*. 2021;27(4):511-9. Epub 20210121. doi: <https://doi.org/10.1016/j.cmi.2021.01.011>. PubMed PMID: 33484843; PubMed Central PMCID: PMC7825872.
150. Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Network Open*. 2020;3(12):e2031756-e. doi: <https://doi.org/10.1001/jamanetworkopen.2020.31756>.
151. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(14):411-5. Epub 2020/04/10. doi: <http://dx.doi.org/10.15585/mmwr.mm6914e1>. PubMed PMID: 32271722; PubMed Central PMCID: PMC7147908
152. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020. Epub 2020/06/20. doi: <https://doi.org/10.1038/s41591-020-0965-6>. PubMed PMID: 32555424.
153. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol*. 2021;19(7):409-24. Epub 20210601. doi: <https://doi.org/10.1038/s41579-021-00573-0>. PubMed PMID: 34075212; PubMed Central PMCID: PMC8167834.
154. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. *Lancet*. 2021;398(10317):2126-8. Epub 20211203. doi: [https://doi.org/10.1016/s0140-6736\(21\)02758-6](https://doi.org/10.1016/s0140-6736(21)02758-6). PubMed PMID: 34871545; PubMed Central PMCID: PMC8640673.
155. Hoffmann F, Eggers D, Pieper D, Zeeb H, Allers K. An observational study found large methodological heterogeneity in systematic reviews addressing prevalence and cumulative

1105 incidence. J Clin Epidemiol. 2020;119:92-9. Epub 20191203. doi:
1106 <https://doi.org/10.1016/j.jclinepi.2019.12.003>. PubMed PMID: 31809847.

1107

1108 Acknowledgements

1109 Dianne Egli-Gany
1110 Michel J. Counotte
1111 Stefanie Hossmann

1112 Funding

1113 Funding was received from the Swiss National Science Foundation (320030_176233, to
1114 NL), <http://www.snf.ch/en/Pages/default.aspx> ; European Union Horizon 2020 research and
1115 innovation programme (101003688, to NL), <https://ec.europa.eu/programmes/horizon2020/en> ;
1116 Swiss government excellence
1117 scholarship(2019.0774, toDBG), [https://www.sbf.admin.ch/sbf/en/home/education/scholarships-](https://www.sbf.admin.ch/sbf/en/home/education/scholarships-and-grants/swiss-government-excellence-scholarships.html)
1118 [and-grants/swiss-government-excellence-scholarships.html](https://www.sbf.admin.ch/sbf/en/home/education/scholarships-and-grants/swiss-government-excellence-scholarships.html) and the Swiss School of Public Health
1119 Global P3HS stipend (to DB-G), [https://ssphplus.ch/en/](https://ssphplus.ch/en/globalp3hs/) globalp3hs/.

1120

1121 The funders had no role in study design, data collection and analysis, decision to publish, or
1122 preparation of the manuscript

1123

1124 Author contributions

1125 **Conceptualization:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low

1126 **Data Curation:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-
1127 Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam, Kaspar
1128 Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William Gildardo
1129 Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov.

1130 **Data extraction:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Eric A. Meyerowitz, Aaron
1131 Richterman, Nirmala Prajapati, William Gildardo Robles-Rodríguez, Nicola Low

1132 **Risk of Bias assessment:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Ingrid Arevalo-
1133 Rodriguez, Anthony Hauser, Aaron Richterman, Nirmala Prajapati, William Gildardo Robles-
1134 Rodríguez, Nicola Low

1135 **Formal Analysis:** Leonie Heron, Georgia Salanti, Nicola Low

1136 **Methodology:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Anthony Hauser, Georgia
1137 Salanti, Nicola Low

1138 **Project Administration:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri

1139 **Supervision:** Georgia Salanti, Nicola Low

1140 **Validation:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia Araujo-Chaveron,
1141 Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam, Kaspar Meili, Eric
1142 A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William Gildardo Robles-
1143 Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Nicola Low

1144 **Writing-Original Draft:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Nicola Low

1145 **Writing- review & editing:** Diana Buitrago-Garcia, Aziz Mert Ipekci, Leonie Heron, Hira Imeri, Lucia
 1146 Araujo-Chaveron, Ingrid Arevalo-Rodriguez, Agustín Ciapponi, Muge Cevik, Muhammad Irfanul Alam,
 1147 Kaspar Meili, Eric A. Meyerowitz, Nirmala Prajapati, Xueting Qiu, Aaron Richterman, William
 1148 Gildardo Robles-Rodríguez, Shabnam Thapa, Ivan Zhelyazkov, Anthony Hauser, Georgia Salanti,
 1149 Nicola Low.

1150

1151 [Competing interests](#)

1152 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf

1153

1154

1155 [Supporting Information](#)

1156 S1. PRISMA Checklist

1157 S1 Text. Search strings

1158 S2 Text. Risk of Bias tool

1159 S1 Form. Data extraction forms

1160 S1 Table. Studies included in version 3.0 and excluded in version 4.0 of the living systematic review

1161 S2 Table. Characteristics of studies reporting on proportion of asymptomatic SARS-CoV-2 infections
 1162 (review question 1 and question 2)

1163 S3 Table. Location of studies contributing data to review question 1

1164 S4 Table. Pooled results other systematic reviews on Asymptomatic

1165 S5 Table. Characteristics of mathematical modelling studies

1166 S1 Fig. Flowchart of identified, excluded, and included records as of 31 January 2020

1167 S2 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection.

1168 S3 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, stratified by
 1169 study design.

1170 S4 Fig. Risk of bias assessment of studies in question 1 and 2

1171 S5 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection, restricted to
 1172 studies with a sample size of at least 10.


1173 S6 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
 1174 outbreak investigations by date of publication.


1175 S7 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
 1176 studies by date of publication.

1177 S8 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
 1178 outbreak investigations by risk of selection bias.

1179 S9 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
 1180 studies by risk of selection bias.


- 1181 S10 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
1182 outbreak investigations by risk of information bias.
- 1183 S11 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
1184 studies by risk of information bias.
- 1185 S12 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
1186 outbreak investigations by risk of misclassification bias.
- 1187 S13 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
1188 studies by risk of misclassification bias.
- 1189 S14 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
1190 outbreak investigations by risk of attrition bias.
- 1191 S15 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
1192 studies by risk of attrition bias.
- 1193 S16 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in contact and
1194 outbreak investigations by risk of bias in all domains.
- 1195 S17 Fig. Forest plot of proportion of people with asymptomatic SARS-CoV-2 infection in screening
1196 studies by risk of bias in all domains.
- 1197 S18 Fig. Assessment of credibility of mathematical modelling studies.





Heterogeneity: $I^2 = 47\%$, $\tau^2 = 0.9514$, $p = 0.13$

Asymptomatic vs. Presymptomatic



Prediction interval

Heterogeneity: not applicable

Presymptomatic vs. Symptomatic



Prediction interval

Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $p = 0.76$

Test for subgroup differences: $\chi^2_2 = 2.10$, $df = 2$ ($p = 0.35$)

